日本のバイオバンキング市場レポート：検体タイプ、バイオバンクタイプ、用途、エンドユーザー、地域別、2025年～2033年

日本のバイオバンキング市場規模は2024年に38億300万米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに56億1,100万米ドルに達し、2025年から2033年にかけて4.4%の成長率（CAGR）を示すと予測しています。個別化医療に対する需要の高まりと、研究やオーダーメイド治療の開発を支援するための生物学的サンプルやデータに対するニーズの高まりが、市場を牽引しています。

本レポートで扱う主な質問

• 日本のバイオバンキング市場はこれまでどのように推移し、今後どのように推移するのか？
• COVID-19が日本のバイオバンキング市場に与えた影響は？
• 日本のバイオバンキング市場の検体タイプ別区分は？
• 日本のバイオバンキング市場のバイオバンクタイプ別の区分は？
• 日本のバイオバンキング市場の用途別区分は？
• 日本のバイオバンキング市場のエンドユーザー別の区分は？
• 日本のバイオバンキング市場のバリューチェーンにおける様々なステージとは？
• 日本のバイオバンキングの主要な促進要因と課題は何か？
• 日本のバイオバンキング市場の構造と主要プレーヤーは？
• 日本のバイオバンキング市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 日本のバイオバンキング市場- イントロダクション

• 概要
• 市場力学
• 業界動向
• 競合情報

第5章 日本のバイオバンキング市場情勢

• 過去および現在の市場動向（2019～2024年）
• 市場予測（2025～2033年）

第6章 日本のバイオバンキング市場- 検体タイプ別の内訳

• 血液製品
• 固形組織
• 細胞株
• 核酸
• その他

第7章 日本のバイオバンキング市場- バイオバンクタイプ別の内訳

• 人口ベースのバイオバンク
• 疾患指向型バイオバンク

第8章 日本のバイオバンキング市場- 用途別の内訳

• 治療
• 研究

第9章 日本のバイオバンキング市場- エンドユーザー別の内訳

• 学術機関
• 製薬およびバイオテクノロジー企業

第10章 日本のバイオバンキング市場- 競合情勢

• 概要
• 市場構造
• 市場企業のポジショニング
• 主要成功戦略
• 競合ダッシュボード
• 企業評価象限

第11章 主要企業のプロファイル

第12章 日本のバイオバンキング市場- 業界分析

• 促進要因・抑制要因・機会
• ポーターのファイブフォース分析
• バリューチェーン分析

第13章 付録

Japan biobanking market size reached USD 3,803 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 5,611 Million by 2033, exhibiting a growth rate (CAGR) of 4.4% during 2025-2033. The increasing demand for personalized medicine, coupled with the growing need for biological samples and data to support research and the development of tailored treatments, is driving the market.

Biobanking is a crucial aspect of modern healthcare and scientific research. It involves the systematic collection, storage, and management of biological samples, such as blood, tissue, and DNA, from individuals for future use in research, diagnostics, and treatment development. Biobanks play a vital role in advancing our understanding of diseases, genetics, and personalized medicine. These repositories preserve specimens and their associated data under strict ethical and regulatory guidelines, ensuring patient privacy and informed consent. Biobanked samples serve as valuable resources for studying diseases, identifying biomarkers, and testing new therapies. They facilitate large-scale, longitudinal studies that can uncover patterns and trends in health and disease over time. Biobanking promotes collaboration among researchers, accelerates medical discoveries, and enhances the potential for tailored treatments based on an individual's genetic makeup. It also supports translational research, bridging the gap between laboratory findings and clinical applications. In summary, biobanking is a critical infrastructure in modern healthcare, advancing medical knowledge and improving patient care.

Japan Biobanking Market Trends:

The biobanking market in Japan is experiencing robust growth due to several key drivers. Firstly, advancements in medical research and the increasing focus on personalized medicine have propelled the demand for biobanking services. These repositories of biological samples enable researchers to access a diverse range of specimens, accelerating their efforts in understanding diseases and developing targeted therapies. Moreover, the growing awareness of the importance of preserving biological materials for future research has prompted both public and private sector investments in biobanking infrastructure. In addition to this, the rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, necessitates extensive biobanking to support the discovery of biomarkers and therapeutic targets. The adoption of genomic medicine and the integration of genetic information into healthcare practices have further amplified the demand for biobanking solutions. Lastly, regulatory initiatives and ethical considerations have strengthened the framework surrounding biobanking, instilling confidence among stakeholders and encouraging their participation. These interconnected drivers are propelling the biobanking market in Japan towards unprecedented growth, promising a future of improved healthcare outcomes and medical breakthroughs.

Japan Biobanking Market Segmentation:

Specimen Type Insights:

• Blood Products
• Solid Tissue
• Cell Lines
• Nucleic Acid
• Others

Biobank Type Insights:

• Population-based Biobanks
• Disease-oriented Biobanks

Application Insights:

• Therapeutics
• Research

End User Insights:

• Academic Institutions
• Pharma and Biotech Companies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan biobanking market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan biobanking market?
• What is the breakup of the Japan biobanking market on the basis of specimen type?
• What is the breakup of the Japan biobanking market on the basis of biobank type?
• What is the breakup of the Japan biobanking market on the basis of application?
• What is the breakup of the Japan biobanking market on the basis of end user?
• What are the various stages in the value chain of the Japan biobanking market?
• What are the key driving factors and challenges in the Japan biobanking?
• What is the structure of the Japan biobanking market and who are the key players?
• What is the degree of competition in the Japan biobanking market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biobanking Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Biobanking Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Biobanking Market - Breakup by Specimen Type

• 6.1 Blood Products
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Solid Tissue
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)
• 6.3 Cell Lines
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2019-2024)
  • 6.3.3 Market Forecast (2025-2033)
• 6.4 Nucleic Acid
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2019-2024)
  • 6.4.3 Market Forecast (2025-2033)
• 6.5 Others
  • 6.5.1 Historical and Current Market Trends (2019-2024)
  • 6.5.2 Market Forecast (2025-2033)

7 Japan Biobanking Market - Breakup by Biobank Type

• 7.1 Population-based Biobanks
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Disease-oriented Biobanks
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)

8 Japan Biobanking Market - Breakup by Application

• 8.1 Therapeutics
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2019-2024)
  • 8.1.3 Market Forecast (2025-2033)
• 8.2 Research
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2019-2024)
  • 8.2.3 Market Forecast (2025-2033)

9 Japan Biobanking Market - Breakup by End User

• 9.1 Academic Institutions
  • 9.1.1 Overview
  • 9.1.2 Historical and Current Market Trends (2019-2024)
  • 9.1.3 Market Forecast (2025-2033)
• 9.2 Pharma and Biotech Companies
  • 9.2.1 Overview
  • 9.2.2 Historical and Current Market Trends (2019-2024)
  • 9.2.3 Market Forecast (2025-2033)

10 Japan Biobanking Market - Competitive Landscape

• 10.1 Overview
• 10.2 Market Structure
• 10.3 Market Player Positioning
• 10.4 Top Winning Strategies
• 10.5 Competitive Dashboard
• 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

• 11.1 Company A
  • 11.1.1 Business Overview
  • 11.1.2 Product Portfolio
  • 11.1.3 Business Strategies
  • 11.1.4 SWOT Analysis
  • 11.1.5 Major News and Events
• 11.2 Company B
  • 11.2.1 Business Overview
  • 11.2.2 Product Portfolio
  • 11.2.3 Business Strategies
  • 11.2.4 SWOT Analysis
  • 11.2.5 Major News and Events
• 11.3 Company C
  • 11.3.1 Business Overview
  • 11.3.2 Product Portfolio
  • 11.3.3 Business Strategies
  • 11.3.4 SWOT Analysis
  • 11.3.5 Major News and Events
• 11.4 Company D
  • 11.4.1 Business Overview
  • 11.4.2 Product Portfolio
  • 11.4.3 Business Strategies
  • 11.4.4 SWOT Analysis
  • 11.4.5 Major News and Events
• 11.5 Company E
  • 11.5.1 Business Overview
  • 11.5.2 Product Portfolio
  • 11.5.3 Business Strategies
  • 11.5.4 SWOT Analysis
  • 11.5.5 Major News and Events

12 Japan Biobanking Market - Industry Analysis

• 12.1 Drivers, Restraints, and Opportunities
  • 12.1.1 Overview
  • 12.1.2 Drivers
  • 12.1.3 Restraints
  • 12.1.4 Opportunities
• 12.2 Porters Five Forces Analysis
  • 12.2.1 Overview
  • 12.2.2 Bargaining Power of Buyers
  • 12.2.3 Bargaining Power of Suppliers
  • 12.2.4 Degree of Competition
  • 12.2.5 Threat of New Entrants
  • 12.2.6 Threat of Substitutes
• 12.3 Value Chain Analysis

13 Appendix